Please login to the form below

Not currently logged in
Email:
Password:

Antares CEO Wotton resigns

He will move to Advanced Cell Technology

antares paul wottonAntares Pharma CEO Paul Wotton is to resign his position to take over as CEO at development-stage biotech company Advanced Cell Technology.

Wotton spent nearly six years in charge of New Jersey-based Antares, having previously served as CEO of Topigen Pharmaceutical.

His replacement at Antares is Eamonn Hobbs, a current board member of the company.  He has over 30 years of experience in the pharma and medical device sectors.

Hobbs was most recently president and CEO of Delcath Systems, a pharma and medical device company specialising in cancer treatment.

“We have worked closely with Eamonn over the past five years as board members and share his vision for the future,” said Leonard Jacob, chairman of the board of directors.

2nd July 2014

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....